Company Filing History:
1 out of 1,630 
1 out of 7 Years Active: 2009
Title: Ulrika Tehler: Innovator in Antiviral Peptide Conjugates
Introduction: Ulrika Tehler, a talented inventor based in Lund, Sweden, has made significant contributions to the field of antiviral research. With a focus on enhancing drug efficacy, she has developed innovative compounds that improve oral bioavailability and target specific transporters in the body.
Latest Patents: Ulrika holds a patent for "Cidofovir peptide conjugates as prodrugs." This invention involves cidofovir-based compounds that have an amino acid, dipeptide, or tripeptide attached to a cidofovir or cyclic cidofovir framework. The patented compounds not only exhibit enhanced oral bioavailability but also demonstrate increased binding to the PepT1 transporter, making them valuable in the treatment of viral infections. Furthermore, her invention provides compositions and methods for treating viral infections, as well as a novel method for preparing cidofovir.
Career Highlights: Throughout her career, Ulrika has been affiliated with esteemed institutions, including the University of Southern California and Tsrl, Inc. Her work at these organizations has contributed to significant advancements in pharmaceutical sciences and antiviral therapies.
Collaborations: Ulrika has collaborated with notable colleagues, including Charles E. McKenna and Boris A. Kashemirov. These collaborations have fostered an environment of innovation and research excellence, further enhancing her contributions to the field.
Conclusion: Ulrika Tehler stands out as a prominent figure in the realm of drug innovation, particularly in the development of antiviral therapies. Her patented work on cidofovir peptide conjugates exemplifies her commitment to advancing medical science and improving treatment options for viral infections. As her career progresses, the impact of her innovations will likely continue to be felt in the pharmaceutical industry and beyond.